mRNA-1982 / Moderna - LARVOL DELTA

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age) (clinicaltrials.gov) - P2 | N=366 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Inflammatory Arthritis • Lyme Disease

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age) (clinicaltrials.gov) - P2 | N=350 | Recruiting | Sponsor: ModernaTX, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Inflammatory Arthritis • Lyme Disease

Monovalent and multivalent OspA mRNA-LNP vaccines elicit functional antibodies and protect against Borrelia burgdorferi in mice. (PubMed, NPJ Vaccines) - P1/2 | "Finally, mice vaccinated two or three times with different dose levels of OspA ST1 mRNA-LNP or with the heptavalent mRNA vaccine were protected against B. burgdorferi infection in a tick-mediated challenge model. The monovalent and the heptavalent OspA mRNA vaccines (mRNA-1982 and mRNA-1975, respectively) are currently undergoing testing in a Phase 1 clinical trial (NCT05975099)."

Journal • Preclinical • Infectious Disease • Inflammatory Arthritis • Lyme Disease

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age) (clinicaltrials.gov) - P2 | N=350 | Not yet recruiting | Sponsor: ModernaTX, Inc.

New P2 trial • Infectious Disease • Inflammatory Arthritis • Lyme Disease

Safety and Immunogenicity of mRNA-1982 and mRNA-1975, mRNA Vaccine Candidates for Prevention of Lyme Disease in Healthy Adults: Interim Results of a Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial (IDWeek 2025) - No abstract available

Clinical • P1/2 data • Infectious Disease • Lyme Disease

A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age (clinicaltrials.gov) - P1/2 | N=807 | Completed | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Inflammatory Arthritis • Lyme Disease

A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age (clinicaltrials.gov) - P1/2 | N=807 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Trial completion date: Mar 2026 ➔ Jul 2025 | Trial primary completion date: Mar 2026 ➔ Jul 2025

Trial completion date • Trial primary completion date • Infectious Disease • Inflammatory Arthritis • Lyme Disease

A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age (clinicaltrials.gov) - P1/2 | N=807 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Inflammatory Arthritis • Lyme Disease

A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age (clinicaltrials.gov) - P1/2 | N=800 | Recruiting | Sponsor: ModernaTX, Inc.

New P1/2 trial • Infectious Disease • Inflammatory Arthritis • Lyme Disease